Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

October 16, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

February 15, 2026

Conditions
Alzheimer Disease
Interventions
DRUG

MAR

Once-daily tablet

Trial Locations (16)

28150

Carolina Research Center, Inc. (Noah Clinical Site 009), Shelby

32174

Neurology Associates of Ormond Beach (Noah Clinical Site 015), Ormond Beach

32720

Accel Research Sites (Noah Clinical Site 019), DeLand

33024

Best Choice Medical and Research Service (Noah Clinical Site 025), Pembroke Pines

33134

Life Well Research Center (Noah Clinical Site 008), Miami

Regenerate Primary Medical Research (Noah Clinical Site 003), Miami

33137

Miami Jewish Health (Noah Clinical Site 023), Miami

33176

International Medical Investigational Centers (Noah Clinical Site 001), Palmetto Bay

33458

Health Awareness (Noah Clinical Site 020), Jupiter

33563

Denali Health Plant City, LLC (Noah Clinical Site 024), Plant City

73099

Tekton Research (Noah Clinical Site 002), Yukon

77450

Olympus Clinical Research (Noah Clinical Site 014), Katy

85260

Scottsdale Clinical Trials (Noah Clinical Site 017), Scottsdale

87109

IMA Clinical Research (Noah Clinical Site 004), Albuquerque

92647

Marvel Clinical Research (Noah Clinical Site 010), Huntington Beach

02131

Boston Clinical Trials (Noah Clinical Site 006), Boston

Sponsors
All Listed Sponsors
lead

Noah Pharmaceuticals, Inc.

INDUSTRY

NCT06597058 - Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill | Biotech Hunter | Biotech Hunter